PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07F 9/38, A61K 31/66 — A1

(11) International Publication Number: **WO 99/20635**

(43) International Publication Date: 29 April 1999 (29.04.99)

(21) International Application Number: PCT/IL98/00508

(22) International Filing Date: 18 October 1998 (18.10.98)

(30) Priority Data:
122009 21 October 1997 (21.10.97) IL

(71) Applicant *(for all designated States except US)*: UNIPHARM LTD. [IL/IL]; P.O. Box 21429, 61213 Tel Aviv (IL).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: TOMER, Zevulun [IL/IL]; Lipsky Street 16, 62195 Tel Aviv (IL).

(74) Agents: HESS, Yitzhak et al.; Dr. Yitzhak Hess & Partners, P.O. Box 6451, 61063 Tel Aviv (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: SALT OF A BISPHOSPHONIC ACID DERIVATIVE

(57) Abstract

The present invention relates to an anhydrous dipotassium alendronic acid salt and the dipotassium alendronic acid salt hydrates e.g. dipotassium alendronic acid salt pentahydrate. The present invention also relates to pharmaceutical preparations comprising as active ingredient the anhydrous dipotassium alendronic acid salt one of the dipotassium alendronic acid salt hydrates. The pharmaceutical preparation may be a tablet, a pellet, a film, sugar or enterocoated tablet or pellet, a capsule, a suspension, a solution, an emulsion, etc.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SALT OF A BISPHOSPHONIC ACID DERIVATIVE

The present invention relates to the anhydrous dipotassium alendronic acid salt and to the dipotassium alendronic acid salt hydrates. (Alendronic acid stands for 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid.)

Alendronic acid and some of its pharmaceutically acceptable salts are known compounds. Said compounds serve for the treatment of diseases of abnormal (ectopic) depositions of calcium salts and the reduction of bone resorption. As such diseases there may be mentioned, inter alia, osteoporosis, menopausal osteoporosis, Paget's disease, myosisitis ossificans, Bechterew's disease, malignant hypercalcemia, metastatic bone disease, periodontal disease, cholelithiasis, nephrolithiasis, urolithiasis, urinary calculus, sclerosis, arthritis, bursistis, neuritis and tetany.

From WO 96/39410 Specification there are known certain pharmaceutical formulations comprising disodium salts of alendronic acid as well as some new disodium salts. However, it has been found that said salts are not entirely satisfactory, as they irritate the digestion system, in particular the Esophagus and are not very soluble.

It has now surprisingly been found that the anhydrous dipotassium alendronic acid salt and the dipotassium alendronic acid salt hydrates, which so far had not been known, irritate the Esophagus less and are more soluble.

The present invention thus consists in the anhydrous dipotassium alendronic acid salt and in the dipotassium alendronic acid salt hydrates.

The present invention consists also in pharmaceutical preparations comprising as active ingredient the anhydrous dipotassium alendronic acid salt one of the dipotassium alendronic acid salt hydrates.

The pharmaceutical preparation may be a tablet, a pellet, a film, sugar or enterocoated tablet or pellet, a capsule, a suspension, a solution, an emulsion, etc. It may comprise in addition to the active ingredient suitable one or more compounds

selected among suitable carriers, diluents, fillers, solvents, lubricants, disintegrants, preservatives, emulsifiers, etc.

The compounds according to the present invention may be prepared by a reaction of the alendronic acid with potassium hydroxide under suitable reaction conditions.

The present invention will now be illustrated with reference to the Examples without being restricted by them.

Example 1

0.5 N of aqueous potassium hydroxide was added with stirring to an aqueous suspension of 3.97 g of Alendronic Acid in 150 ml of distilled water until the pH was 9.2.

The solution obtained was triturated with 400 ml of ethanol. The suspension obtained was left to stand overnight at 4°C. The precipitated solid was filtered off and dried for 20 hours over P_2O_5 in vacuo at 100°C at 26 tor. 3.51 g (yield = 88.4%) of the anhydrous dipotassium alendronic acid salt were obtained.

The compound has the molecular formula: $C_4H_{11}O_7NP_2K_2$

The C H N analysis:

Calc.: H 3.41% C 14.77% N 4.13%

Found: H 3.47% C 14.84% N 4.03%.

Example 2

2 g of the anhydrous dipotassium alendronic acid salt obtained as described in Example 1 were left open on a small glass dish for 24 hours at ambient room conditions. After said period the weight of the product was 2.624 g, i.e.the product gained 0.624 g (31.2%). Thereafter the product was kept under the same conditions for 96 hours. The weight of the product was 2,615 g, 2.635 g and
2.608 g after 48, 72 and 96 hours, respectively. This confirmed that the dipotassium alendronic acid salt pentahydrate was obtained.

The Differential Scanning Calorimetry (DSC) as shown in the annexed Figure and the Thermogravimetric Analysis (TG) confirmed also that said pentahydrate was obtained.

The compound has the molecular formula $C_4H_{11}O_7NP_2K_2.5H_2O$

The H C N analysis:

Calc.:	H 5.10%	C 11.57%	N 3.37%
Found:	H 5.21%	C 11.33%	N 3.28%

Example 3

Preparation of the Granulation Wetting Solution containing Dipotassium Alendronic Acid Salt Pentahydrate

144 g of Dipotassium Alendronic Acid Salt Pentahydrate were dissolved in 550 ml of water.

Preparation of the Powder Mixture

550 g of Calcium Hydrogen Phosphate Dihydrate, 400 g of Corn Starch, 900 g of Microcrystalline Cellulose, 135 g of Pregelatinized Starch and 15 g of Crospovidone were passed through a 30 mesh screen and mixed in a fluid bed granulator.

Granulation step

The granulation wetting solution was sprayed on the powder mixture in a fluid bed granulator to obtain a granulate which was then dried in the fluid bed granulator at an inlet temperature of 50°C.

Preparation of Granulate for Encapsulation

The dried granulate was passed through a 16 mesh sieve and mixed in a drum mixer with 4 g of Magnesium Stearate.

Preparation of Tablets

The granulate was compressed into tablets, each tablet containing 16,8 mg of Dipotassium Alendronic Acid Salt Pentahydrate equivalent to 10 mg of Alendronic Acid.

Example 4

Preparation of the Granulation Wetting Solution containing Dipotassium Alendronic Acid Salt Pentahydrate

144 g of Dipotassium Alendronic Acid Salt Pentahydrate were dissolved in 650 ml of water.

Preparation of the Powder Mixture

600 g of Lactose, 300 g of Corn Starch, 950 g of Microcrystalline Cellulose, 135 g of Pregelatinized Starch and 20 g of Croscarmellose Sodium were passed through a 30 mesh screen and mixed in a fluid bed granulator.

Granulation step

The granulation wetting solution was sprayed on the powder mixture in a fluid bed granulator to obtain a granulate which was then dried in the fluid bed granulator at an inlet temperature of 50°C.

Preparation of Granulate for Encapsulation

The dried granulate was passed through a 16 mesh sieve and mixed in a drum mixer with 4 g of Magnesium Stearate.

Preparation of Tablets

The granulate was compressed into tablets, each tablet containing 16,8 mg of Dipotassium Alendronic Acid Salt Pentahydrate equivalent to 10 mg of Alendronic Acid.

Example 5

144 g of Dipotassuim Alendronic acid salt pentohydrate were mixed with 950 g lactose and 850 g of microcrystalline cellulose.
30 g of Crosspovidone were added to the above blended powders and mixed.
Finally 10 g of Magnesium Stearate were added to the mixed powdres and mixed to an homogenous mixed powders.
The lubricated mixture was compressed to provide tablets, each containing the equivalent of 10 mg Alendronic acid.

Claims

1. The anhydrous dipotassium alendronic acid salt and the dipotassium alendronic acid salt hydrates.
2. The anhydrous dipotassium alendronic acid salt.
3. Dipotassium alendronic acid salt pentahydrate.
4. A pharmaceutical preparation comprising as active ingredient the anhydrous dipotassium alendronic acid salt.
5. A pharmaceutical preparation comprising as active ingredient a dipotassium alendronic acid salt hydrate.
6. A pharmaceutical preparation according to Claim 5, wherein the hydrate is the pentahydrate.
7. A pharmaceutical preparation according to any of Claims 4 to 6 being in the form of a tablet, a pellet, a film , sugar or enterocoated tablet or pellet, a capsule, a solution or an emulsion.
8. A pharmaceutical preparation according to any of Claims 4 to 7 comprising in addition to the active ingredient one or more compounds selected among carriers, diluents, fillers and solvents.
9. A pharmaceutical preparation according to Claim 8 which comprises one or more additives selected among lubricants, disintegrants, preservatives, and emulsifiers.
10. The anhydrous dipotassium alendronic acid salt and the dipotassium alendronic acid salt hydrates as defined in Claim 1 with reference to Examples 1 and 2.


INTEGRATION
DELTA H 114 mJ
15.1 J/g
PEAK 265.4°C
-2.0mW
INTEGRATION
DELTA H 409 mJ
54.3 J/g
PEAK 293.6°C
-5.1mW
INTEGRATION
DELTA H 551 mJ
73.0 J/g
PEAK 121.9°C
-7.1mW
INTEGRATION
DELTA H 1614 mJ
214.0 J/g
PEAK 155.4°C
-20.4mW
INTEGRATION
DELTA H 1761 mJ
233.6 J/g
PEAK 74.3°C
-18.3mW
<exo
10. mW
100
200
300
°C

FIGURE

INTERNATIONAL SEARCH REPORT

Inter... onal Application No
PCT/IL 98/00508

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07F9/38 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 39410 A (MERCK & CO.,INC.) 12 December 1996 cited in the application see the whole document ---	1-10
Y	US 4 922 007 A (GERARD R. KIECZYKOWSKI) 1 May 1990 see particularly column 2, lines 39-42 ---	1-10
Y	US 4 067 971 A (MARION D. FRANCIS) 10 January 1978 see the whole document ---	1-10
Y	US 4 113 861 A (HERBERT A. FLEISCH) 12 September 1978 see the whole document ---	1-10
	-/--	

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
27 January 1999	10/02/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Beslier, L

1

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Intet onal Application No
PCT/IL 98/00508

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 093, no. 7, 18 August 1980 Columbus, Ohio, US; abstract no. 063017, DUKHOVNAYA A I: "Toxicology of hydroxyethylidenediphosphonate salts" XP002091317 see abstract & GIG. TR. NAUCHNO-TEKH. PROG. (430YAD);77; PP.120-1, Sanepidstants.;Moscow; USSR	

1

INTERNATIONAL SEARCH REPORT

information on patent family members

Inte . .onal Application No
PCT/IL 98/00508

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9639410 A	12-12-1996	AU 6148396 A	24-12-1996
		CA 2221844 A	12-12-1996
		EP 0837863 A	29-04-1998
US 4922007 A	01-05-1990	AT 129713 T	15-11-1995
		AU 625704 B	16-07-1992
		AU 5701990 A	13-12-1990
		CA 2018477 A,C	09-12-1990
		DE 69023280 D	07-12-1995
		DE 69023280 T	20-06-1996
		DK 402152 T	04-12-1995
		EP 0402152 A	12-12-1990
		ES 2080116 T	01-02-1996
		FI 93219 B	30-11-1994
		GR 3018379 T	31-03-1996
		HK 69596 A	26-04-1996
		HU 9500204 A	28-08-1995
		IE 69564 B	02-10-1996
		IL 94612 A	30-03-1995
		JP 7048391 A	21-02-1995
		JP 1931325 C	12-05-1995
		JP 3101684 A	26-04-1991
		JP 6062651 B	17-08-1994
		LV 11472 A	20-08-1996
		LV 11472 B	20-12-1996
		NO 177997 B	25-09-1995
		NO 941726 A,B,	10-12-1990
		PT 94306 A,B	08-02-1991
US 4067971 A	10-01-1978	JP 1416471 C	22-12-1987
		JP 53009324 A	27-01-1978
		JP 62021767 B	14-05-1987
US 4113861 A	12-09-1978	BE 866601 A	03-11-1978
		DE 2819112 A	16-11-1978
		JP 54017131 A	08-02-1979
		US 4210643 A	01-07-1980